Ionis Pharmaceuticals Announces Positive Two-Year Data for Diranersen in Alzheimer's Disease

11/17/2026
Impact: 65
Healthcare

Ionis Pharmaceuticals said its partner Biogen presented positive Week 96 results from the Phase 2 CELIA study of investigational tau-targeting therapy diranersen at the CTAD 2026 conference. The data showed continued clinical benefit and slower decline across measured endpoints in patients with early Alzheimer’s disease. The announcement highlights progress in Ionis’s neurology pipeline; the article reported no financial figures or stock-price impact.

AI summary, not financial advice

Share: